The AP2A1 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat human T lymphocyte line, in which the AP2A1 gene has been disrupted. This polyclonal format provides a heterogeneous pool of cells bearing varied CRISPR-mediated genetic disruptions, offering a robust model for studying loss-of-function phenotypes in a lymphoid background. The product enables investigation of AP2A1-dependent processes without the biases of clonal selection, making it suitable for functional genomics, endocytosis research, and immune cell signaling assays.
The parental Jurkat cell line is an immortalized human T lymphocyte model established from a 14-year-old male patient with acute T cell leukemia. Jurkat cells are extensively employed to dissect T cell receptor (TCR) signal transduction, activation mechanisms, and programmed cell death pathways. Their rapid growth, suspension culture characteristics, and well-characterized signaling networks render them an ideal host for genetic perturbation studies aimed at elucidating molecular mechanisms governing immune cell function and malignant transformation.
AP2A1 encodes the alpha-adaptin A subunit of the heterotetrameric adaptor protein complex 2 (AP-2), a pivotal component of clathrin-mediated endocytosis. AP2A1 functions as a scaffold for assembling clathrin coats at the plasma membrane and engages in cargo selection via recognition of sorting signals on transmembrane receptors. Mechanistically, AP2A1 interacts with AP2B1, AP2M1, AP2S1, and directly binds clathrin heavy chain, epsin, AP180, and dynamin to coordinate vesicle formation. The AP-2 complex is regulated upstream by phosphoinositides, ARF GTPases, and receptor tyrosine kinases through PI3K signaling cascades. Downstream, AP2A1-mediated internalization controls the trafficking of key receptors such as the transferrin receptor, low-density lipoprotein (LDL) receptor, and epidermal growth factor receptor (EGFR), thereby modulating signal attenuation and lysosomal degradation. Representative pathway components include dynamin, amphiphysin, Rab5, and EEA1, which further process endocytic vesicles.
In Jurkat T cells, AP2A1-dependent endocytosis governs the internalization of the TCR-CD3 complex and associated signaling molecules, directly impacting T cell activation thresholds and subsequent immune responses. Disruption of AP2A1 in this cell type provides a powerful tool to dissect how clathrin-mediated uptake modulates proximal TCR signaling, cytokine secretion, and apoptotic sensitivity. This knockout model is particularly valuable for exploring the intersection of membrane trafficking with leukemogenesis, given the Jurkat line??s leukemic origin, and for evaluating how endocytic defects contribute to cancer cell survival or drug resistance.
Researchers can employ these polyclonal knockout cells in a variety of functional assays, including Western blotting for AP2A1 protein loss, immunofluorescence microscopy to visualize clathrin-coated pit morphology, transferrin uptake assays to quantify endocytic rates, and flow cytometry to monitor surface expression of receptors such as EGFR or transferrin receptor. Additional applications encompass RT-qPCR for transcriptional profiling, co-immunoprecipitation to assess altered AP-2 complex assembly, and apoptosis assays following TCR stimulation. These cells are also suitable for drug delivery studies targeting endocytic entry routes. For further information, please contact Ascent Research.
